INTRODUCTION: Subcutaneous panniculitis-like T-cell lymphoma (SPTL-AB) and cutaneous gamma/delta T-cell lymphoma (CGD-TCL) are rare T-cell lymphomas with varying clinical courses. There is no standard treatment, although chemotherapy and hematopoietic stem cell transplantation are commonly used. We describe results using bexarotene for children and adults with these disorders. METHODS: We identified 15 patients (12 adults, 3 children) who were treated with bexarotene between 2000 and 2010 from the Memorial Sloan-Kettering Cancer Center lymphoma database, the Stanford Cancer Center Registry, and the National Cancer Institute (NCI) pediatric lymphoma database. There were 8 females and 7 males, with a median age of 45 years (range, 3 years to 85 years). All patients had stage IV disease. Two of 15 and 4 of 15 patients had documented CGD-TCL and SPTL-AB, respectively; others were presumed to have SPTL-AB. Bexarotene was administered at flat doses corresponding to 91 to 339 mg/m(2)/d. Two of 15 patients received concurrent denileukin diftitox. Two children received bexarotene as maintenance therapy and were not evaluable for response. RESULTS: Among those treated with bexarotene alone, the overall response rate (ORR) was 82% (6/11 complete response [CR], 3/11 partial response [PR]). One of the 2 patients treated with concomitant denileukin diftitox responded for an ORR of 10/13 (77%), including 54% CR and 23% PR. Median progression-free survival was 38.4 months; median duration of response was 26.3 months. Six patients developed hypothyroidism and 9 developed hyperlipidemia; one patient developed dose-limiting hypertriglyceridemia. One pediatric patient developed insulin-dependent diabetes mellitus. CONCLUSIONS: In this retrospective series, bexarotene showed a high response rate in SPTL-AB and CGD-TCL. It was generally well-tolerated with durable responses; therefore, bexarotene represents a promising therapy for children and adults with these disorders.
INTRODUCTION:Subcutaneous panniculitis-like T-cell lymphoma (SPTL-AB) and cutaneous gamma/delta T-cell lymphoma (CGD-TCL) are rare T-cell lymphomas with varying clinical courses. There is no standard treatment, although chemotherapy and hematopoietic stem cell transplantation are commonly used. We describe results using bexarotene for children and adults with these disorders. METHODS: We identified 15 patients (12 adults, 3 children) who were treated with bexarotene between 2000 and 2010 from the Memorial Sloan-Kettering Cancer Center lymphoma database, the Stanford Cancer Center Registry, and the National Cancer Institute (NCI) pediatric lymphoma database. There were 8 females and 7 males, with a median age of 45 years (range, 3 years to 85 years). All patients had stage IV disease. Two of 15 and 4 of 15 patients had documented CGD-TCL and SPTL-AB, respectively; others were presumed to have SPTL-AB. Bexarotene was administered at flat doses corresponding to 91 to 339 mg/m(2)/d. Two of 15 patients received concurrent denileukin diftitox. Two children received bexarotene as maintenance therapy and were not evaluable for response. RESULTS: Among those treated with bexarotene alone, the overall response rate (ORR) was 82% (6/11 complete response [CR], 3/11 partial response [PR]). One of the 2 patients treated with concomitant denileukin diftitox responded for an ORR of 10/13 (77%), including 54% CR and 23% PR. Median progression-free survival was 38.4 months; median duration of response was 26.3 months. Six patients developed hypothyroidism and 9 developed hyperlipidemia; one patient developed dose-limiting hypertriglyceridemia. One pediatric patient developed insulin-dependent diabetes mellitus. CONCLUSIONS: In this retrospective series, bexarotene showed a high response rate in SPTL-AB and CGD-TCL. It was generally well-tolerated with durable responses; therefore, bexarotene represents a promising therapy for children and adults with these disorders.
Authors: Dennis D Weisenburger; Kerry J Savage; Nancy Lee Harris; Randy D Gascoyne; Elaine S Jaffe; Kenneth A MacLennan; Thomas Rüdiger; Stefano Pileri; Shigeo Nakamura; Bharat Nathwani; Elias Campo; Francoise Berger; Bertrand Coiffier; Won-Seog Kim; Harald Holte; Massimo Federico; Wing Y Au; Kensei Tobinai; James O Armitage; Julie M Vose Journal: Blood Date: 2011-01-26 Impact factor: 22.113
Authors: Karen S McGinnis; Michael Shapiro; Jacqueline M Junkins-Hopkins; Mitchell Smith; Stuart R Lessin; Carmela C Vittorio; Alain H Rook Journal: Arch Dermatol Date: 2002-06
Authors: M Duvic; K Hymes; P Heald; D Breneman; A G Martin; P Myskowski; C Crowley; R C Yocum Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: Marco Santucci; Nicola Pimpinelli; Daniela Massi; Marshall E Kadin; Chris J L M Meijer; Hans Konrad Müller-Hermelink; Marco Paulli; Janine Wechsler; Rein Willemze; Heike Audring; Maria Grazia Bernengo; Lorenzo Cerroni; Sergio Chimenti; Andreas Chott; José L Díaz-Pérez; Edgard Dippel; Lyn M Duncan; Alfred C Feller; Marie-Louise Geerts; Christian Hallermann; Werner Kempf; Robin Russell-Jones; Christian Sander; Emilio Berti Journal: Cancer Date: 2003-02-01 Impact factor: 6.860
Authors: Petr Andreevich Vasiluev; Olga N Ivanova; Natalia A Semenova; Tatiana V Strokova; Natalia N Taran; Uliana V Chubykina; Marat V Ezhov; Ekaterina Y Zakharova; Elena L Dadli; Sergey I Kutsev Journal: Genes (Basel) Date: 2022-06-14 Impact factor: 4.141
Authors: Bassem M Shoucri; Victor T Hung; Raquel Chamorro-García; Toshi Shioda; Bruce Blumberg Journal: Endocrinology Date: 2018-08-01 Impact factor: 4.736